abbott laboratories (ABT:New York)
Transactions by ABBOTT LABORATORIES (ABT) in the last 6 months
Abbott Laboratories (NYSE:ABT) announces a share repurchase program. Under the program, the company will repurchase up to $3,000 million worth of its shares. The repurchases may be made from time to time as market conditions warrant and subject to regulatory considerations. The company aims to return value to shareholders.
The Board of Directors of Abbott Laboratories has authorized a buyback plan on September 11, 2014.
On September 11, 2014, the company initiated ...
Mylan, Inc. (NasdaqGS:MYL) entered into a business transfer agreement to acquire non-U.S. developed markets specialty and branded generics business of Abbott Laboratories (NYSE:ABT) for approximately $5.3 billion on July 13, 2014. The assets are being acquired on a debt-free basis. In the transaction, Abbott will transfer the assets to Mylan in consideration for 105 million Mylan ordinary shares, representing 21% stake and Mylan will hold 71% stake. Under the agreement, ...
Abbott Laboratories (NYSE:ABT) signed a definitive agreement to acquire GardenHills OOO for approximately $630 million on June 23, 2014. Under the terms of the agreement, Abbott will acquire Garden Hills, the holding company that currently owns a controlling interest in Veropharm, for between approximately $395 million to $495 million depending on GardenHills' share ownership of Veropharm at time of close. If Garden Hills owns 100% of the shares of Veropharm at that ...
|Actavis plc||$235.51 USD||-6.30|
|Danaher Corp||$78.23 USD||-1.22|
|Medtronic Inc||$65.62 USD||-0.60|
|Teva Pharmaceutical Industries Ltd||$51.34 USD||-0.82|
|Thermo Fisher Scientific Inc||$121.70 USD||-1.54|
|View Industry Companies|